KT203 is a potent and selective inhibitor of monoacylglycerol lipase (MAGL), a key enzyme in the endocannabinoid system. It is primarily utilized in pharmacological and medical research to modulate lipid signaling pathways. In cancer studies, KT203 helps investigate its effects on tumor growth, cell proliferation, and survival by inhibiting MAGL activity. It is also widely used in preclinical research for neurological disorders (e.g., pain, anxiety, depression), chronic inflammation, and neuroprotection, where it increases levels of the endocannabinoid 2-arachidonoylglycerol (2-AG) and reduces pro-inflammatory mediators. This makes KT203 a valuable tool for evaluating therapeutic efficacy and safety in combination with other agents before clinical advancement.